ISRG

ANALYST NOTE: ISRG (Intuitive Surgical, Inc.) Date: 2026-06-13 Current Price: $406.78

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 3.1% (Productive)

Setup Classification: FORMING

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED There is no named secular thesis attached to this specific setup at this date. The investment case is not driven by a macro narrative or a specific thematic rotation (e.g., "AI in Healthcare" or "Global Aging"). Instead, the conviction must be derived entirely from the quality of the structural setup and the underlying business fundamentals. The analyst must judge this name strictly on the strength of the earnings data, the validity of the setup structure, and the absence of disconfirming evidence, without inventing a macro driver.

3. The Business

Company Overview: Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care through the development and commercialization of sophisticated robotic-assisted surgical systems. The company operates in the Healthcare sector, specifically within the Medical Devices industry.

Business Model & Operations: The company generates revenue through a "razor-and-blade" ecosystem. It sells high-margin robotic surgical systems (da Vinci) and the Ion endoluminal system, which are then supported by a recurring revenue stream of instruments, accessories, and service contracts.

• Installed Base: As of March 31, 2026, the installed base of da Vinci surgical systems reached approximately 11,395 systems, a 12% increase year-over-year from 10,189 systems (Evidence E11).
• Placement Velocity: In Q1 2026 alone, the company placed 431 da Vinci systems, a 17% increase compared to 367 systems in the prior year period (Evidence E13).
• Procedure Growth: Q1 2026 saw 847,000 da Vinci procedures performed, up 16% from 732,000 in the prior year (Evidence E14).
• Revenue Mix: Q1 2026 revenue grew 23% year-over-year to $2.77 billion. Recurring revenue (instruments, accessories, service) grew 23% to $2.4 billion, accounting for 86% of total revenue (Evidence E5).

Product & Regulatory Updates (Source Date: 2026): Management has aggressively expanded the addressable market through FDA clearances and product launches:

• da Vinci 5: 232 units of the new da Vinci 5 system were placed in Q1 2026 (Evidence E2). In March 2026, FDA clearance was obtained for updated force feedback instruments with extended lives (Evidence E8). In January 2026, clearance was granted for da Vinci 5 in selected thoracoscopically-assisted cardiac procedures (Evidence E9).
• da Vinci SP: In December 2025, FDA clearance was obtained for the SP system in cholecystectomy, hernia repair, appendectomy, and nipple-sparing mastectomy (Evidence E10).
• Ion System: The Ion endoluminal system continues to show strong adoption, with procedures increasing 39% to 43,000 in Q1 2026 (Evidence E1). A study cited by management showed a 23 percentage point increase in early-stage primary lung cancer diagnosis rates (from 46% in 2019 to 69% in 2024) (Evidence E7).

Management Expectations (Source Date: 2026-04-21):

• Procedure Growth: Management expects full-year da Vinci procedure growth to be in the range of 13.5% to 15.5% (Evidence E3).
• Margins: Management updated the non-GAAP gross profit margin forecast to 67.5% – 68.5%, noting a 100 basis point headwind from tariffs and higher input costs (freight, semiconductor memory) (Evidence E4).
• Procedure Mix: Strong growth is noted in cholecystectomy and appendectomy, which combined grew 31%, driven by expanded use during after-hours and weekends (Evidence E6).

4. Archetype and Conviction

Archetype: Quality Compounder ISRG fits the "Quality Compounder" archetype. The business demonstrates high barriers to entry (installed base network effects), recurring revenue dominance (86%), and consistent double-digit growth in both procedures and placements. The company is not a deep value recovery or a cyclical play; it is a structural growth compounder with pricing power and expanding utility.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. The evidence base is robust, with multiple primary sources (earnings transcripts, SEC filings) confirming growth, margin resilience, and regulatory tailwinds.
• Structural Quality: High. The installed base is growing at 12%, and procedure growth is accelerating (16% vs 13.5-15.5% guidance). The margin guidance (67.5-68.5%) shows management is actively managing cost headwinds while maintaining high profitability.
• Rerating Potential: Moderate to High. The combination of strong procedural growth, new system placements (da Vinci 5), and the expansion of the Ion diagnostic platform provides multiple levers for earnings growth. The financial spine shows forward consensus EPS of $10.39 (FY1) and $11.78 (FY2), implying a growth trajectory that could support a multiple expansion if the setup confirms.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Beat: If Q2 guidance or actuals show gross margins holding above 68.5% despite tariff headwinds, it would validate management's cost-control narrative.
• Procedure Acceleration: If Q2 procedure growth exceeds the upper end of the 15.5% guidance, it would signal an acceleration in adoption.

What Would Invalidate the Case:

• Guidance Cut: A reduction in the full-year procedure growth guidance below 13.5% would contradict the current momentum.
• Margin Compression: A significant drop in gross margins below the 67.5% floor, indicating an inability to pass through tariff costs.

Gaps in Evidence:

• International Mix: While US growth is implied, specific data on international market penetration or currency impacts for Q1 2026 is not detailed in the provided evidence.
• Competitive Landscape: No direct evidence regarding competitive pressure or market share shifts from other robotic platforms is provided in the current evidence block.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Q1 da Vinci procedures grew 16% to 847,000; Q1 revenue grew 23% to $2.77 billion with 86% recurring revenue; Installed base grew 12% to 11,395 systems; FDA clearances for da Vinci 5 cardiac and SP mastectomy procedures. Expected path: Management expects full-year procedure growth of 13.5% to 15.5%; continued expansion of the installed base and recurring revenue stream should drive EPS growth toward the FY2 consensus of $11.78. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or a retest of support.